Nemaura Medical Granted UK Trademark “Meta Score,” a Digital Biomarker Term for its Metabolic Health Program
21 juil. 2022 08h00 HE | Nemaura Medical, Inc
Loughborough, England, July 21, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing a...
Nemaura Medical Launches Metabolic Health Program for Employers and Insurers
13 janv. 2022 08h30 HE | Nemaura Medical, Inc
Launch into commercial markets offers opportunities for faster and wider adoption of Miboko program Loughborough, England, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD)...
Nemaura Medical Launches Beta Version of Its Metabolic Health Program
29 sept. 2021 08h30 HE | Nemaura Medical, Inc
MiBoKo, a noninvasive glucose sensor utilizing AI mobile application, addresses a substantial multibillion-dollar market opportunity in healthcare LOUGHBOROUGH, England, Sept. 29, 2021 (GLOBE...